On-Q-ity
研究包含On-Q-ity
获得CB的数据驱动的专家分析见解信息部。德赢体育vwin官方网站
德赢体育vwin官方网站情报分析家提到On-Q-ity CB见解1 德赢体育vwin官方网站CB见解研究短暂,最近在2023年8月1日。
2023年8月1日
463年启动故障事后检验On-Q-ity专利
On-Q-ity提起了2项专利。
申请日 |
授予日期 |
标题 |
相关的话题 |
状态 |
---|---|---|---|---|
12/3/2012 |
|
细胞生物学、集群的区别、生物技术、转录因子,分析化学 |
应用程序 |
申请日 |
12/3/2012 |
---|---|
授予日期 |
|
标题 |
|
相关的话题 |
细胞生物学、集群的区别、生物技术、转录因子,分析化学 |
状态 |
应用程序 |
最新的On-Q-ity新闻
2018年2月2日,
2013年4月12日7:47am On-Q-ity、癌症诊断启动关注循环肿瘤细胞,是正式破产。布鲁斯·布斯On-Q-ity投资者阿特拉斯公司的合作伙伴,证实了沃尔瑟姆,坎布里奇公司的倒闭在他的博客“生活Sci VC”他说最后的资产出售是结束,11月董事会决定后,关掉它们。他的账户发生了什么异常坦率的,给出了风险参与诊断窗口发展尽管有前途的技术。布斯写道,“诊断不是胆小的人的,”该行业是“一个非常艰难的业务面临着许多风险和成本的药物研发但没有好处。”And On-Q-ity, hit with unexpected problems, may have just been ahead of its time. As Booth describes in his blog, On-Q-ity launched with some fanfare in 2009 through the merger of VC-backed diagnostics firms Cellective Dx and DNA Repair Inc., backed by a $26 million Series A led by Mohr Davidow Ventures and also including Bessemer, Physic and Atlas. On-Q-ity founder Mara Aspinall (now head of Roche's Ventana Medical Systems), brought with her a distinguished track record having run Genzyme for years. Other principals brought solid backgrounds from Myriad Genetics, Genomic Health, Dana Farber Cancer Institute and elsewhere, Booth recalled, based on notes he made in support of the company's 2009 Series A. The technology itself also held promise, which was designed to allow clinicians to grab circulating tumor cells from a patient's blood and then count them and detail the type of cancer, enabling, in theory, personalized treatment. Separately, On-Q-ity also was developing DNA repair pathway tissue-based biomarkers to predict drug response for breast and lung cancer. But, as Booth describes, the biomarker research ended up generating disappointing results in an early trial and two more larger tests, sucking up a lot of the Series A financing. A refocus on the circulating tumor cell (CTC) diagnostic program ran into unexpected development problems, leading to the severing of a LabCorp partnership. Then came massive management changes. Booth explains that the company's team made enormous R&D progress and raised a small Series B to help keep things going. But a search for a strategic partner/acquirer to continue work on the circulating tumor cell technology didn't succeed, and the principals decided to wind the company down. So what went wrong? Booth argues in his blog that merging two promising but as yet "cash burning businesses" into a single company ended up being quite challenging, noting that "crashing two Fords together doesn't make a Porsche." He also said that investors should have tranched the funding into stages, to allow for the technology to be validated with smaller financing before rewarding it with more funds. Management instability didn't help, he said. But ultimately, On-Q-ity may have simply been ahead of its time, particularly with CTC diagnostics, launching before outside investors or potential partners were willing to ride out its development. Cedars-Sinai Medical Center/UCLA are making progress with a NanoVelcro Chip that enables the use of CTCs for diagnostics. Epic Sciences also raised a $13 million Series B round last fall to advance its molecular diagnostic test that relies on circulating tumor cells, just to name two of many CTC diagnostic development efforts now gaining traction. - read Booth's full blog entry About the Author
On-Q-ity常见问题(FAQ)
On-Q-ity是何时成立的?
On-Q-ity成立于2009年。
On-Q-ity总部在哪里?
On-Q-ity总部位于林肯街610号,沃尔瑟姆。
On-Q-ity的最新一轮融资是什么?
On-Q-ity的最新一轮融资已经死了。
On-Q-ity筹集了多少钱?
On-Q-ity筹集了总计31.97美元。
On-Q-ity的投资者是谁?
Mohr Davidow On-Q-ity的投资者包括物理企业,合资企业,阿特拉斯公司合格的治疗项目,发现酸性Venture Partners和3。
On-Q-ity的竞争对手是谁?
On-Q-ity的竞争对手包括AltheaDx CivaTech肿瘤学,破译生物科学,Exagen 20/20 GeneSystems和10。
比较On-Q-ity竞争对手
Civatech肿瘤是一个医疗设备公司专注于聚合物的发展基础设备,使用局部治疗癌症,low-dose-rate辐射。公司的制造方法允许精确的封装放射性物质到聚合物结构。这些聚合物短距离放射治疗设备为肿瘤提供医生的治疗方案与low-dose-rate近距离放射疗法。
公司的主要目标是消除不必要的乳房手术,往往错过了发现乳腺癌,促进治疗交付过程,节省公司的医疗系统每年23亿美元。n
CellPoint诊断发展诊断、监控和癌症的分子分析工具。其技术捕获和分析循环肿瘤细胞(ctc)直接从患者的血液。科学和临床数据表明,ctc是源自于原发肿瘤,和评估血液中的ctc的数量可以准确预测癌症患者的生存。
NeoDiagnostix分子发展为治疗癌症的诊断和预后的测试。公司的测试结果消除了歧义在数以百万计的样品分析传统cytomorphology-based细胞分析。公司致力于为医生提供信息,改善病人的护理和治疗。
预测预防Prognomixs愿景是个性化医疗的发展对过敏性疾病的早期发现并发症和个体治疗反应使用基因签名他们最初的重点是糖尿病并发症的诊断工具发生前症状的发展基于基因签名针对个性化针对性预防
Daktari诊断开发产品,临床医生和病人提供重要的诊断信息。Daktari最初的产品是手持CD4细胞计数,旨在使CD4计数由任何人。公司打算把这个血液测试,世界各地数以百万计的人已经获得拯救生命的药物,然而却不能开始治疗由于诊断不足。